Cellular Longevity
Designed to support cellular health and healthy aging.
MOTS-CEpitalonNAD+ Injection
Peptide therapy
MOTS-C, Mitochondria-Derived Research Peptide
A 16-amino-acid peptide encoded in mitochondrial DNA. Preclinical biology is compelling. Human clinical evidence remains limited.
MOTS-C is one of a class of signaling peptides encoded within mitochondrial DNA, a relatively recent discovery that has reframed how researchers think about mitochondria as active signaling hubs rather than passive energy factories. The biology is compelling. The human clinical evidence is not yet there.
This page distinguishes between what the preclinical science shows and what has been validated in humans, so you can make an informed decision about whether this therapy belongs in your protocol.
What it is
About this therapy
MOTS-C (Mitochondrial Open Reading Frame of Twelve S rRNA-c) is a 16-amino-acid peptide encoded by the mitochondrial genome within the 12S rRNA gene. It was discovered in 2015 by Pinchas Cohen's research group, notable because it emerged from a previously overlooked reading frame within mitochondrial DNA.
MOTS-C circulates in blood plasma. Plasma levels decline measurably with age and increase acutely in skeletal muscle after exercise, a finding that led researchers to describe it as a potential exercise mimetic.
In the U.S., MOTS-C is available only as a research peptide through 503A compounding pharmacies with a valid prescription. That status is subject to ongoing FDA regulatory review.
How it works
Mechanism of action
MOTS-C's primary known mechanism is activation of AMPK (AMP-activated protein kinase), a master cellular energy sensor that responds to low cellular energy state. Mechanistic data in cell and animal models is robust.
- AMPK activation enhances glucose uptake in muscle, fatty acid oxidation, and insulin sensitivity, in preclinical models.
- Mitochondrial biogenesis. MOTS-C promotes expression of PGC-1α and NRF1, genes that drive the production of new mitochondria.
- Nuclear translocation. Under metabolic stress, MOTS-C translocates from cytoplasm to the nucleus, where it directly regulates gene expression involved in stress adaptation.
- Anti-inflammatory. MOTS-C reduces NF-κB signaling, lowering pro-inflammatory cytokine output.
In mouse models, MOTS-C administration improved insulin sensitivity, reduced obesity, extended lifespan under metabolic stress, and showed effects comparable to exercise training. These findings generate the clinical interest. They do not confirm equivalent human effects.
Conditions and use cases
Where this therapy may fit
All evidence supporting these use cases is preclinical or early-phase. No human RCTs validate therapeutic efficacy for these indications. Studies suggest signal, not certainty.
- Insulin resistance and metabolic syndrome research, AMPK pathway is well-characterized in preclinical models.
- Age-related metabolic decline. Endogenous levels decline with aging.
- Exercise performance support. Exercise mimetic hypothesis, animal data only.
- Investigational cardiovascular and bone metabolism research.
MOTS-C is appropriate only for adults who provide informed consent acknowledging the absence of human RCTs and who are under close provider supervision.
Expected timeline
What to expect over a care cycle
Week 0 to 2
Initiation and tolerability
Provider initiates compounded protocol after a Good Faith Exam. Tolerability monitored. Phase 1 analog trials noted persistent injection-site reactions.
Week 2 to 4
Tolerability check
Provider reviews tolerance and any symptomatic response. No human RCT defines an expected metabolic delta at this point.
Month 1 to 3
Cycle continuation
Anecdotal compounded protocols run 4 to 12 weeks. Provider reassesses against patient goals.
Month 3 to 6
Cycle review
Long-term human data is absent. Decisions about continued use are individualized after a full clinical review.
Stacks that include this
Designed into Cellular Longevity and Metabolic Reset stacks
Metabolic Reset
Designed to support lean composition and metabolic health.
TesamorelinMOTS-COptional: NAD+
Investment and access
How to access this therapy at Genesis
Genesis Longevity therapies are dispensed only after a complimentary consultation and Good Faith Exam. Schedule yours to receive a personalized plan.
Safety
Side effects and contraindications
Reported side effects
Limited human data, drawn from a Phase 1 analog trial and anecdotal reports.
- Injection site reactions, including persistent nodules (noted in the CB4211 Phase 1 program).
- Increased heart rate and palpitations (anecdotal).
- Insomnia and fever (anecdotal).
- Long-term safety in humans is unknown.
Contraindications and patient selection
- Pregnancy and breastfeeding (no safety data).
- Active malignancy. AMPK modulation effects on cancer biology are unclear.
- Concurrent use of AMPK-affecting drugs (for example metformin), interactions have not been studied.
- Known hypersensitivity to MOTS-C.
- Pediatric patients, no data.
- Competitive athletes subject to WADA testing. MOTS-C is prohibited.
Frequently asked
Frequently asked questions
No. MOTS-C is a research peptide. Its analog CB4211 entered Phase 1 trials, but development has not been continued. It is not approved for any indication in the United States.
Not yet for therapeutic efficacy. The AMPK activation mechanism is well-characterized in cell and animal studies. Human Phase 1 data established early tolerability. No human RCTs have demonstrated therapeutic benefit for metabolic, longevity, or exercise outcomes. Conservative framing: promising biology, unproven clinical outcomes in humans.
No. MOTS-C is described as an exercise mimetic in preclinical work, meaning it activates some of the same cellular pathways. Exercise itself produces a far broader range of physiologic benefits. MOTS-C should be considered a potential complement to, not a substitute for, regular physical activity.
Yes. WADA prohibits MOTS-C. Athletes subject to drug testing should not use this peptide.
Sources
Citations & references
- [1]Lee C et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. PMC9905433.
- [2]Reynolds J et al. MOTS-c, emerging roles in energy homeostasis and disease. PMC9854231.
- [3]Alzheimer's Drug Discovery Foundation, MOTS-C Cognitive Vitality Research Summary. Source
- [4]USADA, What is MOTS-C peptide? Source
- [5]Adjust Clinic, MOTS-C scientific evidence analysis. Source
- [6]Aging-US, Original MOTS-C discovery and exercise-responsive rise. Source
Status & disclosures
- FDA status
- MOTS-C is a research peptide, not FDA-approved. It is currently under FDA 503A peptide review.
- 503A compounding
- Available only through licensed 503A compounding pharmacies under valid physician prescription.
- WADA prohibited
- MOTS-C is on the WADA Prohibited List. Patients subject to sport-specific testing should not use this peptide.
- Evidence basis
- Mechanistic data is preclinical and well-characterized. Human RCTs validating clinical efficacy do not yet exist.
Next step
Talk to a Genesis provider in Colorado Springs.
Schedule a consultation. Physician-led, evidence-graded.
Or keep reading: Or browse the Cellular Longevity stack